Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about APREA THERAPEUTICS, INC.
01/13APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
01/06Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on T..
AQ
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Biotechnology Index
CI
2021Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant..
AQ
2021Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azaci..
AQ
2021Aprea Therapeutics, Inc. Announces Updated Results from Its Phase 2 Trial Evaluating Ep..
CI
2021APREA THERAPEUTICS : Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Ma..
PU
2021APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Aprea Therapeutics Says FDA Has Removed Its Clinical Hold on Study of Eprenetapopt for ..
MT
2021APREA THERAPEUTICS : FDA Lifts Hold on Eprenetapopt Study in Lymphoid Malignancies
DJ
2021Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid M..
AQ
2021Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid M..
CI
2021Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on ..
PU
2021APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
2021Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
2021Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on ..
GL
2021Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
GL
2021Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
GL
2021Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
CI
2021INSIDER SELL : Aprea Therapeutics
MT
2021APREA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Aprea Therapeutics, Inc. Announces Resignation of Johan Christenson from the Board of D..
CI
2021INSIDER SELL : Aprea Therapeutics
MT
2021INSIDER SELL : Aprea Therapeutics
MT
2021APREA THERAPEUTICS : Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advan..
AQ
2021Aprea Therapeutics, Inc. Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) i..
CI
2021Top Premarket Gainers
MT
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from S&P Global BMI Index
CI
2021APREA THERAPEUTICS : to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Soli..
AQ
2021Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Sol..
CI
2021NORTH AMERICAN MORNING BRIEFING : Stock Furures -3-
DJ
2021APREA THERAPEUTICS : JPMorgan Downgrades Aprea Therapeutics to Underweight From Neutral
MT
2021APREA THERAPEUTICS : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $4 from $6,..
MT
2021APREA THERAPEUTICS : Berenberg Bank Downgrades Aprea Therapeutics to Hold From Buy Followi..
MT
2021NORTH AMERICAN MORNING BRIEFING : Weak Chinese -4-
DJ
2021APREA THERAPEUTICS : RBC Cuts Price Target on Aprea Therapeutics to $5 From $6 Amid FDA Ho..
MT
2021APREA THERAPEUTICS : Morgan Stanley Lowers Aprea Therapeutics to Underweight From Equal-We..
MT
2021APREA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2021APREA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Update on ..
PU
2021APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, Fi..
AQ
2021Aprea Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second..
CI
2021Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on..
GL
2021APREA THERAPEUTICS : Says FDA Places Clinical Hold on Lymphoid Malignancy Program
MT
2021Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
GL
2021Aprea Therapeutics, Inc. Announces Clinical Hold on Lymphoid Malignancy Program
CI
2021APREA THERAPEUTICS : FDA Puts Clinical Hold on Lymphoid Malignancy Program
DJ
2021APREA THERAPEUTICS : RBC Reduces Price Target on Aprea Therapeutics to $6 From $7, Maintai..
MT
2021SECTOR UPDATE : Health Care Pulls Back Ahead of Friday Opener
MT
2021Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
CI
2021APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021APREA THERAPEUTICS : Announces a Partial Clinical Hold on Myeloid Malignancy Programs
AQ
2021APREA THERAPEUTICS : Phase 2 Trial of Eprenetapopt With Azacitidine Yields Positive Result..
MT
2021APREA THERAPEUTICS : Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azaci..
AQ
2021Aprea Therapeutics, Inc. Announces Positive Results from Phase 2 Trial of Eprenetapopt ..
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell Small Cap Completeness Inde..
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 3000 Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2000 Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 3000E Growth Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell Microcap Growth Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell Small Cap Comp Growth Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 3000 Growth Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2000 Dynamic Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to Russell Microcap Value Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to Russell 3000E Value Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 3000E Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2500 Growth Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2000 Growth Index
CI
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2500 Index
CI
2021SECTOR UPDATE : Health Care Stocks Edging Lower at Close
MT
2021SECTOR UPDATE : Health Care Stocks Hanging On For Narrow Wednesday Gains
MT
2021Equities Little Changed in US Midday Trading as Markets Await Federal Reserve Rate Deci..
MT
2021MIDDAY REPORT : Wall Street Little Changed, Awaiting FOMC Outcome
MT
2021Wall Street Wavers Pre-Bell Ahead of FOMC Meeting
MT
2021SECTOR UPDATE : Health Care Stocks Mixed In Premarket Trading
MT
2021SECTOR UPDATE : Health Care
MT
1  2  3Next
Upcoming event on APREA THERAPEUTICS, INC.
03/31/22